




# Real-world effectiveness of sofosbuvir/velpatasvir for the treatment of HCV in prison settings

## Real-world analysis of SOF/VEL in 20 prison cohorts across Europe and Canada



526

people in prison with HCV



**Curing HCV in prisons is a crucial step towards the WHO goal of global elimination of viral hepatitis**



SVR12/24

**98.9%**

Infected with HCV genotypes 1–6, treatment-naïve or -experienced, with or without compensated cirrhosis



**23%**

History of mental health disorders



**53%**

History of IDU



**12%**

Active IDU



**15%**

Fibrosis stage F4



**46%**

GT 3 infection

### Authors:

Silvia Rosati, Alexander Wong, Vito Di Marco, Paco Pérez-Hernandez, Guilherme Macedo, Christian Brixko, Roberto Ranieri, Francesca Campanale, Annalisa Basciá, Conrado Fernández-Rodríguez, Victor de Ledinghen, Ivana Maida, Elisabetta Tetti, Alessandra Mangia, Kim Vanstraelen, Cándido Hernández, Michael Mertens, Ioanna Ntalla, Herbert Ramroth & Elena Jiménez

**Citation:** Rosati et al. Future Virology (2022) <https://doi/10.2217/FVL-2022-0016>

**GT:** genotype; **IDU:** injection drug use; **LTFU:** lost to follow-up; **SOF:** sofosbuvir; **SVR:** sustained virologic response; **VEL:** velpatasvir; **WHO:** World Health Organization

©2022 The authors